Fundraising Fox
CuraSen Therapeutics
San Carlos, US · Founded 2016 · 10 known investors
Find your way into CuraSen Therapeutics
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling. It targets psychiatric and neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, neurogenic orthostatic hypotension, PSP, and ALS.
Founders & leadership
CuraSen Therapeutics was founded in 2016 by Anthony P. Ford.
Board
Investors · 10
How we know: Alta Partners's portfolio page · the company's own site · press coverage · Not right? Tell us
How we know: the company's own site · Longitude Capital's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · funding news · press coverage · Not right? Tell us
How we know: the company's own site · press coverage · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$68.6M disclosed across 4 of 5 rounds · 2018–2024
▶$5.8MraisedSep 2024 · 7 investors · BiotechnologyRule 506(b)
- Ron HuntDirector
- Anthony P. FordExecutive Officer, Director
- Benjamin PotterExecutive Officer
- Loretta Tse, Ph.D.Director
- Kathleen Sereda GlaubDirector
- Simon Tate, Ph.D.Director
- Patrick EnrightDirector
- Offering amount
- $45.7M
- Amount sold
- $5.8M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.6MraisedOct 2023 · 11 investors · BiotechnologyRule 506(b)
- Anthony P. FordDirector, Executive Officer
- Simon TateDirector
- Patrick EnrightDirector
- Loretta Tse, Ph.D.Director
- Benjamin PotterExecutive Officer
- Kathleen Sereda GlaubDirector
- Ron HuntDirector
- Offering amount
- $20.8M
- Amount sold
- $17.6M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedNov 2021 · 10 investors · BiotechnologyRule 506(b)
- Patrick EnrightDirector
- Benjamin PotterExecutive Officer
- Anthony P FordDirector, Executive Officer
- Ron HuntDirector
- Loretta Tse, Ph.D.Director
- Simon TateDirector
- Kathleen Sereda GlaubDirector
- Offering amount
- $18M
- Amount sold
- $18M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27.2MraisedJan 2019 · 10 investors · BiotechnologyRule 506(c)
- Henry SkinnerDirector
- Patrick EnrightDirector
- Liam RatcliffeDirector
- Benjamin PotterExecutive Officer
- Anthony P. FordExecutive Officer, Director
- Kathleen Sereda GlaubDirector
- Offering amount
- $54.5M
- Amount sold
- $27.2M
- Minimum investment
- $1
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does CuraSen Therapeutics do?
- CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling. It targets psychiatric and neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, neurogenic orthostatic hypotension, PSP, and ALS.
- Who founded CuraSen Therapeutics?
- CuraSen Therapeutics was founded by Anthony P. Ford in 2016.
- Who are CuraSen Therapeutics's investors?
- CuraSen Therapeutics's investors include Alta Partners, Longitude Capital, abrdn plc, Intermediate Capital Group, Johnson & Johnson Innovation – JJDC, New Leaf Venture Partners, Pappas Capital, Chiesi Ventures and 1 more.
- How much funding has CuraSen Therapeutics raised?
- CuraSen Therapeutics has disclosed $68.6M raised across 4 of its 5 known rounds.
- Where is CuraSen Therapeutics headquartered?
- CuraSen Therapeutics is headquartered in San Carlos, US.